Developer docs
API playgroundTry for free, no card

Search company profiles

Cascadian Therapeutics

Full company profile

uuid00354ak

Namestring
Cascadian Therapeutics
Websiteurl
cascadianrx.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Cascadian Therapeutics was a bio-pharmaceutical company based in Seattle, Washington, that researched, developed, and commercialized therapeutic products for the treatment of cancer. Founded in 1985, the company operated at a small scale of 51-100 employees and was publicly traded on NASDAQ under the ticker CASC before being delisted. The firm pursued a pipeline-driven oncology strategy, executing two disclosed acquisitions: ProlX Pharmaceuticals Corp. in October 2006 (undisclosed consideration) and Alpine Biosciences in August 2014 for approximately $27 million, indicating a roll-up approach to assembling therapeutic assets.

Capital formation activity between 2010 and 2016 totaled approximately $64.9 million across four disclosed funding rounds, with participation from institutional investors including Ayer Capital Management, Cowen Group, Dafna Capital Management, Heights Capital Management, Iroquois Capital, Biotechnology Value Fund, and New Enterprise Associates. Leadership included Robert L. Kirkman as President & CEO and Scott R. Peterson as Chief Scientific Officer. No commercial products, revenue figures, customer relationships, or distribution channels are disclosed in the available data, and the domain CascadianRx.com is currently listed for sale by HugeDomains at $2,995 rather than functioning as an active corporate site, signaling limited current operational presence.

Short descriptiontext

Cascadian Therapeutics was a Seattle-based, clinical-stage bio-pharmaceutical company that researched and developed therapeutic products for cancer treatment. Founded in 1985, it operated with 51-100 employees and pursued oncology assets via acquisition and equity financings prior to its delisting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, cancer drug development, biopharmaceutical products, targeted cancer therapies, clinical-stage biotech
Industry2 codes
1Oncology & Hematology Pharmaceuticals
CodeHLAIAAACPrimaryYes
2Medical Oncology
CodeHLAKAFABPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for the treatment of cancer. The company was founded in 1985, headquartered in Seattle, USA, and historically operated with 51-100 employees focused on oncology drug development. Its prior NASDAQ ticker was CASC, and the company pursued acquisitions of complementary biotech firms such as Alpine Biosciences and ProlX Pharmaceuticals to expand its oncology pipeline.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Oncology therapeutic products
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cascadian Therapeutics

Oncology Biopharmaceuticalscascadianrx.com

Cascadian Therapeutics was a Seattle-based, clinical-stage bio-pharmaceutical company that researched and developed therapeutic products for cancer treatment. Founded in 1985, it operated with 51-100 employees and pursued oncology assets via acquisition and equity financings prior to its delisting.

What Cascadian Therapeutics does

Cascadian Therapeutics was a bio-pharmaceutical company based in Seattle, Washington, that researched, developed, and commercialized therapeutic products for the treatment of cancer. Founded in 1985, the company operated at a small scale of 51-100 employees and was publicly traded on NASDAQ under the ticker CASC before being delisted. The firm pursued a pipeline-driven oncology strategy, executing two disclosed acquisitions: ProlX Pharmaceuticals Corp. in October 2006 (undisclosed consideration) and Alpine Biosciences in August 2014 for approximately $27 million, indicating a roll-up approach to assembling therapeutic assets.

Capital formation activity between 2010 and 2016 totaled approximately $64.9 million across four disclosed funding rounds, with participation from institutional investors including Ayer Capital Management, Cowen Group, Dafna Capital Management, Heights Capital Management, Iroquois Capital, Biotechnology Value Fund, and New Enterprise Associates. Leadership included Robert L. Kirkman as President & CEO and Scott R. Peterson as Chief Scientific Officer. No commercial products, revenue figures, customer relationships, or distribution channels are disclosed in the available data, and the domain CascadianRx.com is currently listed for sale by HugeDomains at $2,995 rather than functioning as an active corporate site, signaling limited current operational presence.

Cascadian Therapeutics firmographics

Firmographics
Name
Cascadian Therapeutics
Website
https://cascadianrx.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
51–100 employees
Short description
Cascadian Therapeutics was a Seattle-based, clinical-stage bio-pharmaceutical company that researched and developed therapeutic products for cancer treatment. Founded in 1985, it operated with 51-100 employees and pursued oncology assets via acquisition and equity financings prior to its delisting.
Ownership category
akta.pro rank

Cascadian Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Oncology & Hematology Pharmaceuticals (HLAIAAAC)
akta.pro secondary industry
Medical Oncology (HLAKAFAB)

Keywords

  • Oncology therapeutics
  • Cancer drug development
  • Biopharmaceutical products
  • Targeted cancer therapies
  • Clinical-stage biotech

Where Cascadian Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Cascadian Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Cascadian Therapeutics product offering

Product offering

Core offering

Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for the treatment of cancer. The company was founded in 1985, headquartered in Seattle, USA, and historically operated with 51-100 employees focused on oncology drug development. Its prior NASDAQ ticker was CASC, and the company pursued acquisitions of complementary biotech firms such as Alpine Biosciences and ProlX Pharmaceuticals to expand its oncology pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncology therapeutic products

Companies that use Cascadian Therapeutics

Customer profile

Ideal customer profiles1 record

Cascadian Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cascadian Therapeutics partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights2 records

Cascadian Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key highlights6 records

Customer concentration

Cascadian Therapeutics social profiles

Digital presence

Cascadian Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cascadian Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Cascadian Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cascadian Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cascadian Therapeutics

What does Cascadian Therapeutics do?

Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for the treatment of cancer. The company was founded in 1985, headquartered in Seattle, USA, and historically operated with 51-100 employees focused on oncology drug development. Its prior NASDAQ ticker was CASC, and the company pursued acquisitions of complementary biotech firms such as Alpine Biosciences and ProlX Pharmaceuticals to expand its oncology pipeline.

When was Cascadian Therapeutics founded?

Cascadian Therapeutics was founded in 1985. It employs 51 to 100 people.

Where is Cascadian Therapeutics based?

Cascadian Therapeutics is headquartered in Seattle, United States, in the North America region.

Does Cascadian Therapeutics have an API?

No public API is recorded for Cascadian Therapeutics.

What industry is Cascadian Therapeutics in?

Cascadian Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRM LAW Announces Investigation of Cascadian Therapeutics, Inc.RM LAW, P.C. has announced an investigation into Cascadian Therapeutics regarding potential breaches of fiduciary duty by its board of directors in connection with a proposed $614 million sale to Seattle Genetics. The transaction would provide shareholders with $10.00 in cash for each share of common stock. The legal action focuses on whether the board acted in the best interests of shareholders during the sale process.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Cascadian Therapeutics, Inc. - CASCMonteverde & Associates PC, a boutique securities law firm based in New York, announced on February 1, 2018, that it has launched an investigation into the Board of Directors and Officers of Cascadian Therapeutics, Inc. for possible breaches of fiduciary duty. The law firm is reaching out to shareholders of Cascadian Therapeutics who wish to obtain additional information or protect their investments. This is a routine shareholder activism alert, as law firms frequently issue such announcements seeking potential plaintiffs for securities litigation.PR NewswireCascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders?Shareholder rights law firm Johnson Fistel announced on January 31, 2018 an investigation into Cascadian Therapeutics' board of directors regarding the proposed sale to Seattle Genetics for $10.00 per share in cash. The law firm is examining whether the board breached fiduciary duties, particularly whether alternatives to the acquisition were adequately pursued and if shareholders are receiving the best possible price. The investigation comes as Cascadian reported that its pivotal registrational trial of tucatinib for HER2-positive metastatic breast cancer remains on track.GlobeNewswireCascadian Therapeutics Announces 2018 Outlook and Recent ProgressCascadian Therapeutics announced its 2018 outlook and recent progress for tucatinib, its lead HER2 inhibitor. The company reported Q4 2017 results, including a subgroup analysis showing prolonged progression-free survival, and plans to update HER2CLIMB enrollment and report interim MOUNTAINEER data. It also aims to publish Phase 1b study results and pursue EMA PRIME designation.GlobeNewswireProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerCascadian Therapeutics announced that tucatinib combined with standard agents showed prolonged progression-free survival in a subgroup of HER2+ metastatic breast cancer patients. In a pooled analysis of 77 patients, 22% achieved prolonged PFS, including those with brain metastases. Results will be presented at the 2017 San Antonio Breast Cancer Symposium.GlobeNewswireCascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal CancerCascadian Therapeutics announced the FDA granted orphan drug designation to tucatinib for HER2+ metastatic colorectal cancer. The designation qualifies the drug for development incentives, including tax credits and 7-year marketing exclusivity. The company is supporting an investigator-initiated study evaluating tucatinib for this indication.GlobeNewswireCascadian Therapeutics Announces Changes to Board of DirectorsCascadian Therapeutics appointed Robert Azelby to its board and retired Richard Jackson. Azelby, currently executive vice president and chief commercial officer at Juno Therapeutics, will bring experience in product development and commercial operations. The company is advancing tucatinib in late-stage development.PR NewswireHealthcare Stocks on Investors' Radar -- Alkermes, Teleflex, Cascadian Therapeutics, and InspireMDThis article provides a market commentary covering trading performance and recent developments for four healthcare sector companies: Alkermes, Teleflex, Cascadian Therapeutics, and InspireMD. Alkermes reported Q4 2016 revenues of $213.5 million, up 31% year-over-year, while InspireMD reported Q4 2016 revenue of $322,000, down from $516,000 in the same period the prior year. Teleflex announced CEO Benson Smith's retirement effective December 31, 2017, and Cascadian Therapeutics disclosed the termination of a letter agreement with investor group BVF, effective March 4, 2017. The article notes the Healthcare sector's generally solid balance sheets and rising demand, while cautioning that political uncertainty around the Affordable Care Act may fuel continued volatility.PR NewswireTechnical Reports on Biotech Stocks -- Biogen, Alnylam Pharma, Cascadian Therapeutics, and Marinus PharmaThe US biotech sector demonstrated strength at the start of 2017, with the Nasdaq Biotechnology index rising 8.1% since year-end 2016, outpacing the S&P 500's 1.3% gain. Biogen shares closed at $297.79 with a slight 0.41% decline, while Alnylam Pharma gained 2.78% to $44.71, and Cascadian Therapeutics dropped 4.02% to $4.77. Key company developments included Biogen exercising an option for an exclusive worldwide license agreement with Amunix Operating Inc., Marinus Pharmaceuticals receiving FDA Orphan Drug Designation for ganaxolone to treat Fragile X Syndrome, and Alnylam announcing an executive departure and promotion.GlobeNewswireCascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support RegistrationCascadian Therapeutics amended its HER2CLIMB Phase 2 trial of tucatinib to a single pivotal study, increasing the sample size to about 480 patients. Updated Phase 1b data show a median progression-free survival of 7.8 months and an overall response rate of 61 percent. The trial will present results at the 2016 San Antonio Breast Cancer Symposium.